Floatz logo

Adebelimab

Extensive-stage Small Cell Lung Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3Active
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
89/ 100

Competitive context

290 Active assets in the Extensive-stage Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
vx-970
National Cancer Institute (NCI)
Phase 2BBB
Veliparib
Central European Society for Anticancer Drug Research
Phase 2BB
hs-20093
Shanghai Hansoh Biomedical Co., Ltd
Phase 3BB
Carboplatin
University of Maryland, Baltimore
Phase 4BB

View all 50 →

Same molecule, other indications

Adebelimab is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
62 / 100
View asset →
cancerDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →